Mucuna pruriens for Parkinson's disease

Low-cost preparation method, laboratory measures and pharmacokinetics profile

Erica Cassani, Roberto Cilia, Janeth Laguna, Michela Barichella, Manuela Contin, Emanuele Cereda, Ioannis U. Isaias, Francesca Sparvoli, Albert Akpalu, Kwabena Ofosu Budu, Maria Teresa Scarpa, Gianni Pezzoli

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background Parkinson's disease (PD) is a progressive neurological condition. Levodopa (LD) is the gold standard therapy for PD patients. Most PD patients in low-income areas cannot afford long-term daily Levodopa therapy. The aim of our study was to investigate if Mucuna pruriens (MP), a legume with high LD content that grows in tropical regions worldwide, might be potential alternative for poor PD patients. Methods We analyzed 25 samples of MP from Africa, Latin America and Asia. We measured the content in LD in various MP preparations (dried, roasted, boiled). LD pharmacokinetics and motor response were recorded in four PD patients, comparing MP vs. LD + Dopa-Decarboxylase Inhibitor (DDCI) formulations. Results Median LD concentration in dried MP seeds was 5.29%; similar results were obtained in roasted powder samples (5.3%), while boiling reduced LD content up to 70%. Compared to LD + DDCI, MP extract at similar LD dose provided less clinical benefit, with a 3.5-fold lower median AUC. Conclusion Considering the lack of a DDCI, MP therapy may provide clinical benefit only when content of LD is at least 3.5-fold the standard LD + DDCI. If long-term MP proves to be safe and effective in controlled clinical trials, it may be a sustainable alternative therapy for PD in low-income countries.

Original languageEnglish
Pages (from-to)175-180
Number of pages6
JournalJournal of the Neurological Sciences
Volume365
DOIs
Publication statusPublished - Jun 15 2016

Fingerprint

Mucuna
Cost of Illness
Levodopa
Parkinson Disease
Pharmacokinetics
Dopa Decarboxylase
Latin America
Controlled Clinical Trials
Complementary Therapies
Fabaceae
Powders

Keywords

  • Levodopa
  • Mucuna pruriens
  • Parkinson's disease

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Mucuna pruriens for Parkinson's disease : Low-cost preparation method, laboratory measures and pharmacokinetics profile. / Cassani, Erica; Cilia, Roberto; Laguna, Janeth; Barichella, Michela; Contin, Manuela; Cereda, Emanuele; Isaias, Ioannis U.; Sparvoli, Francesca; Akpalu, Albert; Budu, Kwabena Ofosu; Scarpa, Maria Teresa; Pezzoli, Gianni.

In: Journal of the Neurological Sciences, Vol. 365, 15.06.2016, p. 175-180.

Research output: Contribution to journalArticle

Cassani, E, Cilia, R, Laguna, J, Barichella, M, Contin, M, Cereda, E, Isaias, IU, Sparvoli, F, Akpalu, A, Budu, KO, Scarpa, MT & Pezzoli, G 2016, 'Mucuna pruriens for Parkinson's disease: Low-cost preparation method, laboratory measures and pharmacokinetics profile', Journal of the Neurological Sciences, vol. 365, pp. 175-180. https://doi.org/10.1016/j.jns.2016.04.001
Cassani, Erica ; Cilia, Roberto ; Laguna, Janeth ; Barichella, Michela ; Contin, Manuela ; Cereda, Emanuele ; Isaias, Ioannis U. ; Sparvoli, Francesca ; Akpalu, Albert ; Budu, Kwabena Ofosu ; Scarpa, Maria Teresa ; Pezzoli, Gianni. / Mucuna pruriens for Parkinson's disease : Low-cost preparation method, laboratory measures and pharmacokinetics profile. In: Journal of the Neurological Sciences. 2016 ; Vol. 365. pp. 175-180.
@article{6c0482cc407b4c6b87a5de3b89aa2794,
title = "Mucuna pruriens for Parkinson's disease: Low-cost preparation method, laboratory measures and pharmacokinetics profile",
abstract = "Background Parkinson's disease (PD) is a progressive neurological condition. Levodopa (LD) is the gold standard therapy for PD patients. Most PD patients in low-income areas cannot afford long-term daily Levodopa therapy. The aim of our study was to investigate if Mucuna pruriens (MP), a legume with high LD content that grows in tropical regions worldwide, might be potential alternative for poor PD patients. Methods We analyzed 25 samples of MP from Africa, Latin America and Asia. We measured the content in LD in various MP preparations (dried, roasted, boiled). LD pharmacokinetics and motor response were recorded in four PD patients, comparing MP vs. LD + Dopa-Decarboxylase Inhibitor (DDCI) formulations. Results Median LD concentration in dried MP seeds was 5.29{\%}; similar results were obtained in roasted powder samples (5.3{\%}), while boiling reduced LD content up to 70{\%}. Compared to LD + DDCI, MP extract at similar LD dose provided less clinical benefit, with a 3.5-fold lower median AUC. Conclusion Considering the lack of a DDCI, MP therapy may provide clinical benefit only when content of LD is at least 3.5-fold the standard LD + DDCI. If long-term MP proves to be safe and effective in controlled clinical trials, it may be a sustainable alternative therapy for PD in low-income countries.",
keywords = "Levodopa, Mucuna pruriens, Parkinson's disease",
author = "Erica Cassani and Roberto Cilia and Janeth Laguna and Michela Barichella and Manuela Contin and Emanuele Cereda and Isaias, {Ioannis U.} and Francesca Sparvoli and Albert Akpalu and Budu, {Kwabena Ofosu} and Scarpa, {Maria Teresa} and Gianni Pezzoli",
note = "Ricercatore distaccato presso IRCCS a seguito Convenzione esclusiva con Universit{\`a} di Bologna (Contin Manuela)",
year = "2016",
month = "6",
day = "15",
doi = "10.1016/j.jns.2016.04.001",
language = "English",
volume = "365",
pages = "175--180",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",

}

TY - JOUR

T1 - Mucuna pruriens for Parkinson's disease

T2 - Low-cost preparation method, laboratory measures and pharmacokinetics profile

AU - Cassani, Erica

AU - Cilia, Roberto

AU - Laguna, Janeth

AU - Barichella, Michela

AU - Contin, Manuela

AU - Cereda, Emanuele

AU - Isaias, Ioannis U.

AU - Sparvoli, Francesca

AU - Akpalu, Albert

AU - Budu, Kwabena Ofosu

AU - Scarpa, Maria Teresa

AU - Pezzoli, Gianni

N1 - Ricercatore distaccato presso IRCCS a seguito Convenzione esclusiva con Università di Bologna (Contin Manuela)

PY - 2016/6/15

Y1 - 2016/6/15

N2 - Background Parkinson's disease (PD) is a progressive neurological condition. Levodopa (LD) is the gold standard therapy for PD patients. Most PD patients in low-income areas cannot afford long-term daily Levodopa therapy. The aim of our study was to investigate if Mucuna pruriens (MP), a legume with high LD content that grows in tropical regions worldwide, might be potential alternative for poor PD patients. Methods We analyzed 25 samples of MP from Africa, Latin America and Asia. We measured the content in LD in various MP preparations (dried, roasted, boiled). LD pharmacokinetics and motor response were recorded in four PD patients, comparing MP vs. LD + Dopa-Decarboxylase Inhibitor (DDCI) formulations. Results Median LD concentration in dried MP seeds was 5.29%; similar results were obtained in roasted powder samples (5.3%), while boiling reduced LD content up to 70%. Compared to LD + DDCI, MP extract at similar LD dose provided less clinical benefit, with a 3.5-fold lower median AUC. Conclusion Considering the lack of a DDCI, MP therapy may provide clinical benefit only when content of LD is at least 3.5-fold the standard LD + DDCI. If long-term MP proves to be safe and effective in controlled clinical trials, it may be a sustainable alternative therapy for PD in low-income countries.

AB - Background Parkinson's disease (PD) is a progressive neurological condition. Levodopa (LD) is the gold standard therapy for PD patients. Most PD patients in low-income areas cannot afford long-term daily Levodopa therapy. The aim of our study was to investigate if Mucuna pruriens (MP), a legume with high LD content that grows in tropical regions worldwide, might be potential alternative for poor PD patients. Methods We analyzed 25 samples of MP from Africa, Latin America and Asia. We measured the content in LD in various MP preparations (dried, roasted, boiled). LD pharmacokinetics and motor response were recorded in four PD patients, comparing MP vs. LD + Dopa-Decarboxylase Inhibitor (DDCI) formulations. Results Median LD concentration in dried MP seeds was 5.29%; similar results were obtained in roasted powder samples (5.3%), while boiling reduced LD content up to 70%. Compared to LD + DDCI, MP extract at similar LD dose provided less clinical benefit, with a 3.5-fold lower median AUC. Conclusion Considering the lack of a DDCI, MP therapy may provide clinical benefit only when content of LD is at least 3.5-fold the standard LD + DDCI. If long-term MP proves to be safe and effective in controlled clinical trials, it may be a sustainable alternative therapy for PD in low-income countries.

KW - Levodopa

KW - Mucuna pruriens

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=84964612273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964612273&partnerID=8YFLogxK

U2 - 10.1016/j.jns.2016.04.001

DO - 10.1016/j.jns.2016.04.001

M3 - Article

VL - 365

SP - 175

EP - 180

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

ER -